The abstract is read at the publisher; the summary is JClub's.
Stage IV neuroblastoma shows a lymphocyte-depleted, myeloid-skewed tumor immune microenvironment, with CD45+ leukocytes comprising a median 1.8% of cells and TAMs dominating CD45+ populations.
- Why it matters: Immune infiltration and macrophage biology vary across neuroblastoma stages, but the spatial immune composition and prevalence of targetable receptors needed for macrophage-directed immunotherapy are not well defined.
- What they did: Using multiplexed immunofluorescence on 185 FFPE tissue cores from 39 patients with four antibody panels covering 32 proteins, they mapped immune/stromal phenotypes by single-cell image analysis and linked them to stage, MYCN status, prior treatment, and survival.
- The result: TAMs co-expressed CD40, CSF1R, and CD163, with Clever-1 on 41% of macrophages and CD200R virtually absent; higher CD45+ and cytotoxic T fractions predicted better overall survival, while CD47+CD45- enrichment predicted worse.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.